Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 65
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Crit Care Nurs Q ; 46(1): 48-65, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36415067

RESUMEN

Surgical emergencies are common in the critical care setting and require prompt diagnosis and management. Here, we discuss some of the surgical emergencies involving the gastrointestinal, hepatobiliary, and genitourinary sites. In addition, foreign body aspiration and necrotizing soft-tissue infections have been elaborated. Clinicians should be aware of the risk factors, keys examination findings, diagnostic modalities, and medical as well as surgical treatment options for these potentially fatal illnesses.


Asunto(s)
Urgencias Médicas , Unidades de Cuidados Intensivos , Humanos , Factores de Riesgo
2.
Crit Care Nurs Q ; 46(1): 17-34, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36415065

RESUMEN

Neurological emergencies carry significant morbidity and mortality, and it is necessary to have a multidisciplinary approach involving the emergency physician, the neurologist, the intensivist, and the critical care nursing staff. These disorders can be broadly divided into noninfectious and infectious etiologies. In this article, we review a few of the neurological emergencies that present to the neurological intensive unit, with emphasis on convulsive status epileptics, myasthenia gravis, Guillain-Barré syndrome, meningitis, encephalitis, and brain abscess.


Asunto(s)
Enfermería de Cuidados Críticos , Urgencias Médicas , Humanos , Unidades de Cuidados Intensivos
3.
Crit Care Nurs Q ; 46(4): 417-425, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37684737

RESUMEN

Female patients are at a greater risk for infections such as urinary tract infections and mastitis, as well as complications from abortions/miscarriages, and sexually transmitted infections. This review highlights risk factors, pathogenesis, complications, diagnostic, and treatment modalities associated with the following infections: mastitis, sexually transmitted diseases, postpartum/abortion-related infections, and urinary tract infections.


Asunto(s)
Aborto Inducido , Mastitis , Enfermedades de Transmisión Sexual , Infecciones Urinarias , Embarazo , Femenino , Humanos , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/etiología , Aborto Inducido/efectos adversos , Factores de Riesgo , Infecciones Urinarias/diagnóstico , Infecciones Urinarias/etiología , Mastitis/etiología
4.
Infection ; 49(3): 511-519, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33528813

RESUMEN

PURPOSE: Gram-negative bacteria (GNB) are a leading cause of bloodstream infections (BSI) and management is complicated by antibiotic resistance. The Accelerate Pheno™ system (ACC) can provide rapid organism identification and antimicrobial susceptibility testing (AST). METHODS: A retrospective, pre-intervention/post-intervention study was conducted to compare management of non-critically ill patients with GNB BSI before and after implementation of a bundled initiative. This bundled initiative included dissemination of a clinical decision algorithm, ACC testing on all GNB isolated from blood cultures, real-time communication of results to the Antimicrobial Stewardship Program (ASP), and prospective audit with feedback by the ASP. The pre-intervention period was January 2018 through December 2018, and the post-intervention period was May 2019 through February 2020. RESULTS: Seventy-seven and 129 patients were included in the pre-intervention and post-intervention cohorts, respectively. When compared with the pre-intervention group, the time from Gram stain to AST decreased from 46.1 to 6.9 h (p < 0.001), and the time to definitive therapy (TTDT) improved from 32.6 to 10.5 h (p < 0.001). Implementation led to shorter median total duration of antibiotic therapy (14.2 vs 9.5 days; p < 0.001) and mean hospital length of stay (7.9 vs 5.3 days; p = 0.047) without an increase in 30-day readmissions (22.1% vs 14%; p = 0.13). CONCLUSION: Implementation of an ASP-bundled approach incorporating the ACC aimed at optimizing antibiotic therapy in the management GNB BSI in non-critically ill patients led to reduced TTDT, shorter duration of antibiotic therapy, and shorter hospital length of stay without adversely affecting readmission rates.


Asunto(s)
Programas de Optimización del Uso de los Antimicrobianos , Bacteriemia , Infecciones por Bacterias Gramnegativas , Antibacterianos/uso terapéutico , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Bacterias Gramnegativas , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Humanos , Pruebas de Sensibilidad Microbiana , Estudios Retrospectivos
5.
Crit Care Nurs Q ; 43(4): 343-348, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32833771

RESUMEN

Coronavirus disease-2019 (COVID-19) was declared a pandemic by the World Health Organization on March 11, 2020. Following this, there has been a rapid development in policies and strategies to contain and mitigate the pandemic. One of such strategies involves the development and utilization of testing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative organism of COVID-19. In this article, we explore the diagnostic modalities for COVID-19 based on the available information to date.


Asunto(s)
Betacoronavirus/aislamiento & purificación , Técnicas de Laboratorio Clínico/métodos , Infecciones por Coronavirus/diagnóstico , Neumonía Viral/diagnóstico , COVID-19 , Prueba de COVID-19 , Infecciones por Coronavirus/epidemiología , Humanos , Pandemias , Neumonía Viral/epidemiología , Reproducibilidad de los Resultados , SARS-CoV-2
6.
Crit Care Nurs Q ; 43(4): 349-368, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32833772

RESUMEN

Coronavirus disease 2019 (COVID-19) has resulted in an unprecedented pandemic, challenging practitioners to identify safe and effective therapeutic options in a limited amount of time. The rapid genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided a significant number of therapeutic targets. Repurposed and investigational agents are being studied for use in COVID-19. Although knowledge is rapidly expanding in regard to COVID-19 and there is promise with a few agents, there are no definitely proven effective therapies at this time. Supportive care remains the mainstay of therapy while ongoing clinical trials are being conducted.


Asunto(s)
Ácido Ascórbico/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/terapia , Humanos , Inmunización Pasiva , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Tratamiento Farmacológico de COVID-19 , Sueroterapia para COVID-19
7.
Eur J Clin Microbiol Infect Dis ; 38(7): 1377-1382, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-31119574

RESUMEN

The objective of this study was to identify potential false-positive urine Legionella pneumophila (Legionella) enzyme immunoassay test results. A total of 107 consecutive patients with positive EIA tests were retrospectively analyzed over a 34-month period. Concurrent blood, urine, and sputum cultures, as well as chest radiographic findings, were reviewed in these patients. Twenty patients (19%) had no radiographic evidence of pulmonary disease despite a positive EIA test. In those 20 patients, 14 also had growth of non-Legionella bacteria. Of patients with an infiltrate or opacity on chest imaging, only 27 had Legionella sputum cultures obtained, with Legionella culture growth occurring in 7 (26%). Nine other patients had negative Legionella sputum cultures but the growth of another pathogenic organism in blood, sputum, and/or urine cultures. Pseudomonas aeruginosa was the most common organism isolated, found in 20% of patients in the entire cohort. Twenty-five patients (23%) were characterized as having probable false-positive Legionella urinary antigen EIA testing, and an additional 17 patients (16%) were characterized as having possible false-positive Legionella EIA tests. Our findings suggest that urine Legionella EIA tests may lead to a substantial number of cases being misdiagnosed as Legionaries' disease in patients with non-Legionella bacterial colonization or infection.


Asunto(s)
Antígenos Bacterianos/orina , Técnicas para Inmunoenzimas , Legionella pneumophila/aislamiento & purificación , Enfermedad de los Legionarios/diagnóstico , Enfermedad de los Legionarios/orina , Urinálisis , Antígenos Bacterianos/inmunología , Bacterias/aislamiento & purificación , Errores Diagnósticos , Reacciones Falso Positivas , Humanos , Estudios Retrospectivos , Sensibilidad y Especificidad , Esputo/microbiología , Tórax/diagnóstico por imagen , Tórax/microbiología
8.
Crit Care Nurs Q ; 42(4): 431-447, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31449153

RESUMEN

Acute respiratory distress syndrome (ARDS) is an inflammatory form of lung injury in response to various clinical entities or inciting events, quite frequently due to an underlying infection. Morbidity and mortality associated with ARDS are significant. Hence, early recognition and targeted treatment are crucial to improve clinical outcomes. This article encompasses the most common infectious etiologies of ARDS and their clinical presentations and management, along with commonly encountered infectious complications in such patients.


Asunto(s)
Neumonía/complicaciones , Síndrome de Dificultad Respiratoria/etiología , Sepsis/complicaciones , Humanos , Síndrome de Dificultad Respiratoria/mortalidad , Síndrome de Dificultad Respiratoria/patología
10.
Transpl Infect Dis ; 19(4)2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28467620

RESUMEN

Adenovirus (AdV) infections in transplant recipients may cause invasive disease. We present a case of granulomatous interstitial nephritis secondary to AdV infection in a renal transplant recipient that was initially interpreted as acute graft rejection on histopathology. Specific testing based on clinical suspicion, however, aided in making an accurate diagnosis. We present a retrospective review of all cases of AdV infection in renal transplant recipients to date, and analyze outcomes based on different treatment modalities for this disease.


Asunto(s)
Infecciones por Adenovirus Humanos/diagnóstico , Trasplante de Riñón/efectos adversos , Nefritis Intersticial/diagnóstico , Adenoviridae , Infecciones por Adenovirus Humanos/etiología , Infecciones por Adenovirus Humanos/patología , Infecciones por Adenovirus Humanos/virología , Anciano , Femenino , Rechazo de Injerto , Humanos , Nefritis Intersticial/etiología , Nefritis Intersticial/patología , Nefritis Intersticial/virología , Estudios Retrospectivos , Receptores de Trasplantes
11.
J Infect Chemother ; 23(3): 180-184, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27681233

RESUMEN

Intravenous vancomycin is a widely used antibiotics, but it causes different types of cutaneous hypersensitivity reactions, ranging from maculopapular rash, red-man syndrome, drug rash with eosinophilia and systemic symptoms, IgA bullous dermatosis, leukocytoclastic vasculitis, Stevens-Johnsons syndrome, to IgE-mediated anaphylaxis. We report an elderly patient with the end-stage renal disease presented with diffuse palpable purpura while receiving IV vancomycin therapy for methicillin-resistant Staphylococcus aureus septicemia. Histopathology of skin biopsy revealed perivascular infiltrates of leukocytoclastic debris with necrosis of the small-sized blood vessels. Direct immunofluorescence analysis demonstrated vivid IgA plus C3 immune-complex deposits localized to the vessel walls, and no immune complexes were noted on the dermoepidermal junction. There was no IgG or IgM immunoreactivity detected on the tissue specimen. Rheumatologic disease work-ups were negative. A diagnosis of vancomycin-associated Henoch-Schönlein variant of vasculitis was made. Vancomycin was substituted by daptomycin, and the purpuric skin rashes were resolved. Since vancomycin is a commonly used antibacterial agent, clinicians are encouraged to have a heightened awareness of this rare adverse skin reaction. Early recognition and prompt discontinuation of the medication is the key in management. As it is not an Ig-E mediated reaction, desensitization of vancomycin or re-challenge with vancomycin is not recommended as re-exposure to the drug may result in a recurrence of similar manifestations with potential permanent renal failure.


Asunto(s)
Vasculitis por IgA/inducido químicamente , Vancomicina/efectos adversos , Anciano , Biopsia/métodos , Humanos , Masculino , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Piel/patología , Infecciones Estafilocócicas/tratamiento farmacológico , Vancomicina/uso terapéutico
13.
Crit Care Nurs Q ; 39(2): 161-75, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26919677

RESUMEN

Infections that are typically innocuous in immunocompetent persons may cause significant disease states in immunocompromised hosts. These individuals may be immunosuppressed secondary to many different causes such as drugs, malignancy, solid-organ or hematopoietic stem cell transplantation, HIV/AIDS, or anatomic reasons (asplenia). These immunocompromised hosts are at high risk for developing opportunistic infections. Here, we discuss some of these infections caused by bacteria, fungi, viruses, and parasites. Clinicians should be aware of the risk factors, common clinical presentations, diagnostic modalities, and treatment options for these potentially fatal illnesses.


Asunto(s)
Huésped Inmunocomprometido , Infecciones Oportunistas/diagnóstico , Infecciones Oportunistas/microbiología , Infecciones Bacterianas/diagnóstico , Humanos , Enfermedades Pulmonares Fúngicas/diagnóstico , Infecciones Oportunistas/inmunología , Factores de Riesgo
15.
Mycoses ; 58(1): 22-6, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25476184

RESUMEN

Severely immunocompromised patients such as those with haematological malignancies and haematopoietic stem cell transplant recipients are at an increased risk of acquiring invasive mould infections. Fusarium, a ubiquitous fungus, can cause potentially fatal infections in such hosts. It usually manifests as skin lesions, fevers and sino-pulmonary infections. Brain abscesses have been reported, but are relatively uncommon. We report a case of a 50-year-old patient with acute lymphocytic leukaemia and failed autologous peripheral stem cell transplant that presented with new onset seizures and was found to have Fusarium solani brain abscess. Nasal route was the presumed mode of entry of the fungus into the cerebrum. Treatment comprised surgical excision of the lesion, and antimycotic therapy with liposomal amphotericin B and voriconazole. Despite aggressive therapy, patient succumbed to the disease. We have provided an overview of infections secondary to Fusarium, along with a review of the central nervous system involvement by this pathogenic mould.


Asunto(s)
Absceso Encefálico , Infecciones Fúngicas del Sistema Nervioso Central , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Anfotericina B/administración & dosificación , Antifúngicos/uso terapéutico , Absceso Encefálico/diagnóstico por imagen , Absceso Encefálico/tratamiento farmacológico , Absceso Encefálico/microbiología , Infecciones Fúngicas del Sistema Nervioso Central/diagnóstico por imagen , Infecciones Fúngicas del Sistema Nervioso Central/tratamiento farmacológico , Infecciones Fúngicas del Sistema Nervioso Central/microbiología , Resultado Fatal , Femenino , Fusariosis/diagnóstico por imagen , Fusariosis/tratamiento farmacológico , Fusariosis/microbiología , Fusarium/citología , Fusarium/aislamiento & purificación , Humanos , Huésped Inmunocomprometido , Persona de Mediana Edad , Trasplante de Células Madre de Sangre Periférica , Radiografía , Convulsiones , Voriconazol/administración & dosificación , Voriconazol/uso terapéutico
16.
South Med J ; 107(9): 597-9, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25188627

RESUMEN

OBJECTIVES: The 2010 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America treatment guidelines for Clostridium difficile infections (CDI) recommend oral metronidazole for mild-to-moderate disease and oral vancomycin for severe disease. Given that disease severity is easily determined by the peripheral white blood cell count and serum creatinine level, a computerized decision support (CDS) pathway to guide treatment is inherently appealing. Because providers often override or ignore the computer-based alerts, the proposed CDS pathway should be justified before implementation. METHODS: We undertook this study to ascertain the frequency of nonadherence to CDI guidelines. Between October 1, 2007 and September 30, 2008, a total of 229 cases were screened and 78 cases were included in the study, which took place at a 661-bed acute tertiary care teaching hospital. RESULTS: During the year-long study of CDI cases at our tertiary care hospital, 61.5% (48/78) of the patients received an antibiotic regimen that was not recommended by the 2010 guidelines. Among the 35 patients with mild-to-moderate CDI, 85.7% (30/35) received the recommended treatment of oral metronidazole monotherapy; in contrast, among the 43 patients with severe disease, none (0/43) received the recommended treatment of oral vancomycin monotherapy (P < 0.01). Moreover, 17.9% (14/78) of patients received concurrent oral metronidazole and vancomycin, a regimen that is not recommended anywhere in the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America guidelines and which may be associated with a poor outcome. Patients who received combination oral metronidazole and vancomycin were not more likely to have comorbidities or severe CDI compared with those who received a single antibiotic agent. CONCLUSIONS: As a result of this study, we plan to educate our providers on the treatment of CDI through a CDS pathway in an effort to increase guideline adherence, decrease inappropriate antibiotic use, and potentially improve patient outcomes.


Asunto(s)
Antibacterianos/uso terapéutico , Clostridioides difficile , Infecciones por Clostridium/tratamiento farmacológico , Adhesión a Directriz , Metronidazol/uso terapéutico , Vancomicina/uso terapéutico , Vías Clínicas , Sistemas de Apoyo a Decisiones Clínicas , Humanos , Selección de Paciente , Guías de Práctica Clínica como Asunto , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
17.
Indian J Orthop ; 58(2): 144-150, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38312906

RESUMEN

Purpose: Antimicrobial cement spacer (ACS) placement has been a cornerstone of two-stage management of prosthetic hip and knee infection. Pharmacokinetic modelling has described peak systemic antibiotic concentrations within the first 24-48 h post-operatively, followed by rapid clearance. A few studies have, however, identified detectable tobramycin levels in patients with a post-operative decline in creatinine clearance. Our study sought to determine how frequently detectable serum tobramycin levels occurred within the first 72 h following ACS placement in all patients regardless of baseline or subsequent changes in renal function, whether these levels correlated with tobramycin spacer dosage, creatinine clearance, or potential nephrotoxicity risk factors, and whether any patients developed acute kidney injury within the 14-day post-operative period. Methods: We prospectively enrolled patients with prosthetic hip or knee infections and subsequent ACS placement from October 2017 to February 2020. Patient comorbidities (chronic kidney disease, diabetes mellitus, chronic liver disease, chronic obstructive pulmonary disease, and atrial fibrillation), Charleston Comorbidity Index score, risk factors for post-operative nephrotoxicity (perioperative hypotension and nephrotoxic agent receipt), total tobramycin dosage, post-operative days 1 and 3 serum tobramycin concentrations, and serum creatinine and creatinine clearance throughout a 14-day post-operative period were recorded. Results: A total of 20 patients were enrolled, comprising 20 spacers with a median total tobramycin dosage of 4.80 g with an interquartile range (IQR) of 4.13-7.20 g. Thirteen patients had a median detectable post-operative day 1 serum tobramycin concentration of 0.80 (IQR 0.50-1.60) mcg/mL. Five of these 13 patients had a median detectable post-operative day 3 serum tobramycin concentration of 0.80 (IQR 0.50-1.10) mcg/mL. A correlation was not found between serum tobramycin drug levels and patient comorbidities, receipt of nephrotoxic medications, or baseline and subsequent post-operative creatinine clearance up to day 14. Conclusion: The majority of patients who underwent tobramycin ACS placement had detectable serum tobramycin levels in the immediate post-operative period, but most reached undetectable levels within 72 h. There were no reliable perioperative predictors of detectable drug levels.

18.
J Infect Chemother ; 19(1): 162-5, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22669505

RESUMEN

Ochrobactrum anthropi, a Gram-negative bacillus, is an unusual human pathogen. It has been implicated primarily in catheter-related bloodstream infections. Sporadic cases of infection at other body sites have been reported. Pneumonia, however, is an exceedingly rare clinical manifestation; only one case has been reported in the medical literature so far. We present another case of lower respiratory tract infection secondary to O. anthropi in a patient who was critically ill, but recovered with a favorable outcome. We have provided an overview of clinical manifestations, diagnosis, and treatment of infections due to this rare microorganism.


Asunto(s)
Infecciones por Bacterias Gramnegativas/microbiología , Ochrobactrum anthropi/aislamiento & purificación , Neumonía Bacteriana/microbiología , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Infecciones por Bacterias Gramnegativas/complicaciones , Infecciones por Bacterias Gramnegativas/diagnóstico , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Ochrobactrum anthropi/efectos de los fármacos , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/diagnóstico , Neumonía Bacteriana/tratamiento farmacológico , Insuficiencia Respiratoria/microbiología , Choque Séptico/microbiología
19.
J Am Assoc Nurse Pract ; 35(10): 652-657, 2023 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-37260274

RESUMEN

ABSTRACT: After the lifting of COVID-19 restrictions, international travel has demonstrated recovery to prepandemic levels. Travel, particularly to tropical regions, can be associated with contracting various infectious diseases. For this reason, collecting a travel history is a necessity when assessing any patient with vague infectious symptoms, most notably fever. Early suspicion, identification, and treatment of tropical illnesses can be lifesaving. This case study concerns a patient who recently traveled to Africa and is under evaluation for fever in the emergency department. The proper approach to the febrile traveler and the pathophysiology, diagnosis, and treatment of malaria are reviewed.


Asunto(s)
COVID-19 , Malaria , Humanos , COVID-19/complicaciones , Fiebre/etiología , Malaria/diagnóstico , Malaria/complicaciones , Viaje , Diagnóstico Diferencial
20.
J Appl Lab Med ; 8(3): 559-567, 2023 05 04.
Artículo en Inglés | MEDLINE | ID: mdl-36759952

RESUMEN

BACKGROUND: Direct specimen sequencing (DSS) offers the promise of enhanced pathogen detection and disease diagnosis. METHODS: A single healthcare network, retrospective chart review over a 3-year period was completed for all cases in which DSS was submitted, in addition to conventional testing (CT) for workup of an infectious disease. We sought to compare results (concordance and discordance) from these 2 techniques in order to evaluate any additional yield from DSS over CT. Additionally, we calculated mean turnaround time (TAT) and average cost for obtaining DSS on all specimens. RESULTS: A total of 23 patients' specimens were sent for DSS. DSS and CT concordance occurred in 91% (21/23) of cases. DSS testing was able to identify specific pathogens in 17.4% (4/23) of patients, out of which 4% (1/23) were discordant. The respective mean TAT and total cost per specimen for DSS were 6 days and $821.52 (range $573-$1590), respectively. CONCLUSIONS: In our limited cohort of patients, there was significant concordance between the 2 testing modalities primarily due to negative tests. DSS did not provide significant additional yield in the infectious diagnosis in our cohort compared to CT. Short TAT may provide advantage in the detection of fastidious organisms, but high cost remains a limitation. Larger sample size may reveal a clinically meaningful difference.


Asunto(s)
Derivación y Consulta , Humanos , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA